Structure-based design of hyaluronidase inhibitors
... Hyaluronic acid (hyaluronan), along with chondroitin-, keratan- and dermatane sulfate, heparin and heparan sulfate, is a member of the family of glycosaminoglycanes which are mostly linear polymers of high molecular weight composed of aminosugars (N-acetylglucosamine or N-acetylgalactosamine) and ur ...
... Hyaluronic acid (hyaluronan), along with chondroitin-, keratan- and dermatane sulfate, heparin and heparan sulfate, is a member of the family of glycosaminoglycanes which are mostly linear polymers of high molecular weight composed of aminosugars (N-acetylglucosamine or N-acetylgalactosamine) and ur ...
Capoten, Oral solution
... endogenous bradykinin, patients receiving ACE inhibitors are subject to a variety of adverse reactions producing effects ranging from relatively mild, such as cough (see Precautions), to serious such as the following: Head and neck angioedema: Severe life-threatening angioedema has been reported rar ...
... endogenous bradykinin, patients receiving ACE inhibitors are subject to a variety of adverse reactions producing effects ranging from relatively mild, such as cough (see Precautions), to serious such as the following: Head and neck angioedema: Severe life-threatening angioedema has been reported rar ...
Rx Only USE IN PREGNANCY
... survived the acute phase of myocardial infarction and did not have active ischemia. Patients had left ventricular dysfunction (LVD), defined as a resting left ventricular ejection fraction ≤40%, but at the time of randomization were not sufficiently symptomatic to require ACE inhibitor therapy for h ...
... survived the acute phase of myocardial infarction and did not have active ischemia. Patients had left ventricular dysfunction (LVD), defined as a resting left ventricular ejection fraction ≤40%, but at the time of randomization were not sufficiently symptomatic to require ACE inhibitor therapy for h ...
DDD107498: A novel clinical candidate for malaria
... • Dundee Kinase Panel (125 human kinases) > 10 µM • Broad Screening (receptors, enzymes, ion channels) ...
... • Dundee Kinase Panel (125 human kinases) > 10 µM • Broad Screening (receptors, enzymes, ion channels) ...
Structural analysis of histamine receptors and its application in drug
... Structure-based methods can be used effectively in several stages of drug design. For example, a structural protein model can be used to map the binding site, and explore novel sites for ligand design. These sites may provide opportunities increasing affinity and/or selectivity. Moreover, protein mo ...
... Structure-based methods can be used effectively in several stages of drug design. For example, a structural protein model can be used to map the binding site, and explore novel sites for ligand design. These sites may provide opportunities increasing affinity and/or selectivity. Moreover, protein mo ...
kuliah farmakologi antidepresan
... ◦ In another study, clonazepam proved as effective for treating panic disorders as alprazolam, and termination did not cause rebound anxiety symptoms because of clonazepam's long elimination half-life. ◦ Clonazepam displays low lipid solubility, it is less likely to cause anterograde amnesia compare ...
... ◦ In another study, clonazepam proved as effective for treating panic disorders as alprazolam, and termination did not cause rebound anxiety symptoms because of clonazepam's long elimination half-life. ◦ Clonazepam displays low lipid solubility, it is less likely to cause anterograde amnesia compare ...
Nonsteroidal Anti-inflammatory Drugs
... • Sensitization to structurally similar R2 side chain groups (infrequent) ...
... • Sensitization to structurally similar R2 side chain groups (infrequent) ...
Pharmacology 19c – Epilepsy and Anticonvulsants
... Side effects and Pharmacokinetics - ½ life 29 hrs (monoPx), 15 hrs (enzyme inducing co-medication), 60 hrs (valproate co-medication). - Metabolised by hepatic glucuronidation (no phase 1 metabolism). Side effects Main one is rash, others are less common and include headache, blood dyscrasia, ataxia, ...
... Side effects and Pharmacokinetics - ½ life 29 hrs (monoPx), 15 hrs (enzyme inducing co-medication), 60 hrs (valproate co-medication). - Metabolised by hepatic glucuronidation (no phase 1 metabolism). Side effects Main one is rash, others are less common and include headache, blood dyscrasia, ataxia, ...
University of Groningen Merits and demerits of the converting
... unknown. It is possible that auto-antibodies,which result from immunodysregulation,play a part in the pathogenesis.As for the clinical impact of the histologicallesions,it is asyet unknown whether MGP will progress to renal function loss by the development of a thickened GBM or, alternatively,may he ...
... unknown. It is possible that auto-antibodies,which result from immunodysregulation,play a part in the pathogenesis.As for the clinical impact of the histologicallesions,it is asyet unknown whether MGP will progress to renal function loss by the development of a thickened GBM or, alternatively,may he ...
Structural Basis for Interaction of Inhibitors with Cyclin
... ATP and cyclin A [31] clearly shows that there are five significant conformational changes: (a) the two domains are more open in the ternary complex, thus, pushing the phosphate-loop (P loop) toward the N-terminal domain; (b) the conformation of the triphosphate of ATP and surrounding residues are d ...
... ATP and cyclin A [31] clearly shows that there are five significant conformational changes: (a) the two domains are more open in the ternary complex, thus, pushing the phosphate-loop (P loop) toward the N-terminal domain; (b) the conformation of the triphosphate of ATP and surrounding residues are d ...
Enzymes
... -The electronic effects of various substituents will effect on a drug's ionization or polarity. -effect on a drug can pass through cell membranes and strongly bind to a receptor. -measure of the electron withdrawing (+ σ) or electron donating ability (-σ) of a substituent ...
... -The electronic effects of various substituents will effect on a drug's ionization or polarity. -effect on a drug can pass through cell membranes and strongly bind to a receptor. -measure of the electron withdrawing (+ σ) or electron donating ability (-σ) of a substituent ...
Pharmacophore Approach in Drug Discovery
... In other words, if they are able to exert a strong interaction with the main target, they exert also less strong interactions with some other biological targets. Most of these targets are unrelated to the primary therapeutic activity of the compound. The objective is then to proceed to a reversal of ...
... In other words, if they are able to exert a strong interaction with the main target, they exert also less strong interactions with some other biological targets. Most of these targets are unrelated to the primary therapeutic activity of the compound. The objective is then to proceed to a reversal of ...
PDF - Journal of Applied Pharmaceutical Science
... and apoptotic bodies. Compared with control groups, groups treated with 300 µmol/L and 400 µmol/L nimesulide had many more cells with apoptotic characteristics. This observation is of interest because of the putative antitumor effect of NSAIDs. IBUPROFEN Ibuprofen is (2RS)-1[4-(2-methyl propyl) phen ...
... and apoptotic bodies. Compared with control groups, groups treated with 300 µmol/L and 400 µmol/L nimesulide had many more cells with apoptotic characteristics. This observation is of interest because of the putative antitumor effect of NSAIDs. IBUPROFEN Ibuprofen is (2RS)-1[4-(2-methyl propyl) phen ...
Anti Hyperlipidaemic Agents
... d. Compensatory mechanism of the loss of LDL will ↑VLDL and therefore ↑plasma TG level 3. It most be clear that Resins is not effective in patient having homozygous Familial Hypercholeterolaemia due to the absence of LDL receptor in the liver, but useful in heterozygous ...
... d. Compensatory mechanism of the loss of LDL will ↑VLDL and therefore ↑plasma TG level 3. It most be clear that Resins is not effective in patient having homozygous Familial Hypercholeterolaemia due to the absence of LDL receptor in the liver, but useful in heterozygous ...
Discovery and development of ACE inhibitors
The discovery of an orally inactive peptide from snake venom established the important role of angiotensin converting enzyme (ACE) inhibitors in regulating blood pressure. This led to the development of Captopril, the first ACE inhibitor. When the adverse effects of Captopril became apparent new derivates were designed. Then after the discovery of two active sites of ACE: N-domain and C-domain, the development of domain-specific ACE inhibitors began.